Amphastar Pharma (AMPH) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amphastar Pharmaceuticals Reports Net Revenues of $53.9 Million for the Second Quarter Ended June 30, 2015
August 12, 2015 4:00 PM EDTRANCHO CUCAMONGA, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the second quarter ended June 30, 2015.
Net revenues of $53.9 million for the second quarter GAAP net loss of $6.6 million, or $0.15 per diluted share for the second quarter Adjusted non-GAAP net loss of $3.9 million, or $0.09 per diluted share for the second quarter  Three Months Ended June 30, Six Months Ended June 30,  2015 2014 2015 2014  (in thousands, except per share data)... More